Third Quarter 2025 Results Presentation October 30, 2025 Cautionary notes This presentation, the information contained herein, any other materials provided in connection with this presentation and any oral remarks accompanying this presentation (collectively, the "Presentation"), has been prepared by Alamos Gold Inc. ("Alamos" or the "Company") solely for information purposes. No stock exchange, securities commission or other regulatory authority has approved or disapproved the contained information. This P ...

Financial Performance - Total revenues reached $595.9 million, a 9.7% increase year-over-year[17] - SaaS revenues grew by 20% to $199.8 million[17] - Annual Recurring Revenue (ARR) increased by 10.7% to $2.05 billion[17] - Non-GAAP earnings per share (EPS) increased by 17.9% to $2.97[17] - Recurring revenues accounted for 86% of total revenues, amounting to $512.4 million, representing a 10.7% year-over-year growth[25] - Non-recurring revenues were $111.3 million, representing 14% of total revenues[25] - Maintenance revenues declined by 3.7%[25] - Transaction revenues increased by 11.5%[25] Future Outlook - The company projects total revenues between $2.335 billion and $2.360 billion for 2025, implying approximately 10% growth[38, 39] - The company anticipates non-GAAP diluted EPS to be between $11.30 and $11.50, and GAAP diluted EPS to be between $7.28 and $7.48 for 2025[41] - The company estimates free cash flow margin between 25% and 27% for 2025[42]

Third Quarter 2025 Earnings Call John Plant: Executive Chairman and Chief Executive Officer Ken Giacobbe: EVP and Chief Financial Officer October 30, 2025 Important Information Forward–Looking Statements This presentation contains statements that relate to future events and expectations and as such constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements include those containing such words as "anticipates", "believes", "coul ...

Investor Presentation O c t o b e r 2 0 2 5 Forward-Looking Statements Statements contained in this investor presentation that are not historical facts are forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking statements include words or phrases such as "anticipate," "believe," "estimate," "expect," "intend," "likely," "outlook," "plan," "project," "could," "may," "might," "s ...

Company Overview - UFP Industries converts 7% of North American softwood lumber, manufacturing value-added products for residential, commercial construction, outdoor living, packaging, and industrial applications[9] - The company's Q3 2025 TTM net sales reached $6.5 billion, with an adjusted EBITDA of $589 million[38] - UFP operates 213 facilities worldwide and employs approximately 14,000 people[38] Financial Performance & Goals - UFP aims for annual unit sales growth of 7-10%, with new product sales accounting for 10% of total net sales[58] - The company targets a 12.5% adjusted EBITDA margin and seeks incremental returns on new investments exceeding a 15% hurdle rate[58, 60] - UFP's Q3 2025 TTM adjusted EBITDA margin was 9.1%, exceeding 2019 levels by approximately 200 bps[126] Business Segments - UFP Retail Solutions had Q3 2025 TTM net sales of $2.514 billion, with new products representing 3.5% of net sales[86] - UFP Packaging's Q3 2025 TTM net sales were $1.6 billion, with new products accounting for 11.2% of net sales[86] - UFP Construction reported Q3 2025 TTM net sales of $2.051 billion, with new products contributing 8.3% of net sales[86] Capital Allocation - The company is committed to maintaining a conservative capital structure, with net debt to adjusted EBITDA below 1.5x[60] - UFP has a CapEx plan of $275 million to $300 million in 2025 and an ongoing share repurchase program[152] - The company is investing $100 million over 5 years through the UFP Venture Fund to spur external growth and innovation[82]

Financial Performance - CNX generated $226 million in Q3 2025 free cash flow[3], marking the 23rd consecutive quarter of positive free cash flow generation[3, 5] - The company anticipates approximately $640 million in free cash flow for 2025[5], driven by additional asset sales[5] - CNX has generated approximately $27 billion in free cash flow since Q1 2020[6] - The company's Q3 2025 cash operating margin was 62%[3], with an expected 2025 cash operating margin of 63%[3] - Q3 2025 fully burdened cash costs, before DD&A, were $109 per Mcfe[3], with an expected ~$112 per Mcfe for 2025[3] Capital Allocation - CNX repurchased 61 million shares in Q3 2025 at an average price of $3012 per share, totaling $182 million[5] - Since the inception of the buyback program in 2020, CNX has repurchased approximately 43% of its outstanding shares[3, 5, 12] - CNX has repurchased 957 million shares for $18 billion since Q3 2020 at an average price of $1886[11] Balance Sheet and Guidance - CNX's adjusted net debt increased in the first quarter of 2025 due to the Apex Energy acquisition[13] - The company has significant liquidity under credit facilities, with combined elected commitments of $20 billion[18] - CNX updated its 2025 free cash flow guidance to approximately $640 million, which includes approximately $115 million in expected asset sales[5, 20, 21] - The updated guidance for 2025 FCF per share is ~$475, based on shares outstanding of 134,832,658 as of 10/20/2025[20, 22] Environmental Performance - CNX captured approximately 91 million metric tons of waste methane CO₂e, which is nearly 20 times greater than scope 1 emissions[28]

Financial Performance - The company's Q3 2025 sales were $6222 million, compared to $6142 million in Q2 2025 and $3979 million in Q3 2024[23] - Adjusted EBITDA for Q3 2025 was $859 million, up from $670 million in Q2 2025 and $366 million in Q3 2024[24] - The Adjusted EBITDA margin increased to 138% in Q3 2025, compared to 109% in Q2 2025 and 92% in Q3 2024[25] - The company reported an Adjusted EBIT loss of $240 million in Q3 2025, compared to an Adjusted EBIT of $239 million in Q2 2025 and $158 million in Q3 2024[26] - Adjusted Operating EPS was $(043) in Q3 2025, compared to $018 in Q2 2025 and $033 in Q3 2024[27] - Free cash flow was $150 million in Q3 2025, compared to $54 million in Q2 2025 and $309 million in Q3 2024[28] Packaging Solutions North America (PS NA) - PS NA YTD Adjusted EBITDA increased from $123 billion in 2024 to $172 billion in 2025, a 40% increase[16] - PS NA YTD Adjusted EBITDA margin increased by 370 bps, from 120% in 2024 to 157% in 2025[16] - PS NA Adjusted EBITDA increased from $515 million in Q2 2025 to $655 million in Q3 2025[30] - The company expects PS NA Adjusted EBITDA to be $600 million in Q4 2025[37] Packaging Solutions EMEA (PS EMEA) - PS EMEA Adjusted EBITDA increased from $194 million in Q2 2025 to $209 million in Q3 2025[30] - The company expects PS EMEA Adjusted EBITDA to be $230 million in Q4 2025[44] Strategic Initiatives and Targets - The company is targeting approximately $06 billion in incremental Adjusted EBITDA for 2026 from cost out and commercial actions[49] - The company updated its 2025 net sales target to approximately $240 billion and Adjusted EBITDA target to approximately $30 billion[51] - The company updated its 2027 net sales target to approximately $255 billion and Adjusted EBITDA target to approximately $50 billion[51]

Financial Performance & Guidance - Third Quarter 2025 Normalized FFO per share was $0.88, a 10% year-over-year increase[10, 11] - Total Company Same-Store Cash NOI grew by 8% year-over-year in the third quarter of 2025, primarily driven by SHOP[10, 11] - SHOP Same-Store Cash NOI experienced a 16% year-over-year growth, with U S growth leading at 19%[10, 11] - Ventas increased its 2025 senior housing investment guidance to $2.5 billion, up from the previous $2.0 billion[11, 16] - The company raised $2.6 billion in equity, which includes $0.5 billion from unsettled forward sales agreements as of October 2025[11] - Ventas increased Normalized FFO per share midpoint guidance to $3.47, a $0.03 increase from the previous $3.44 midpoint[15] - SHOP Same-Store Cash NOI growth guidance increased to 14%-16% from the previous 12%-16%[16] Portfolio & Strategy - Ventas is executing a focused strategy to drive growth, including delivering profitable organic growth in senior housing, capturing value-creating external growth focused on senior housing, and driving strong execution and cash flow generation throughout the portfolio[17] - The company's U S SHOP portfolio is actively managed for significant occupancy upside, with average occupancy around 85%[23, 24] - Ventas has accumulated 1.3+ billion senior housing data points to optimize markets, assets, and operators[40]

Financial Performance - Total revenue reached $17601 million, a 54% increase compared to Q3 2024[12, 17] - Key product revenue grew by 104%, reaching $12 billion[12] - Non-GAAP earnings per share (EPS) increased by $584 to $702[12] - The company raised the midpoint of full-year revenue guidance by over $2 billion[10] Product Highlights - Lilly's U S incretin analogs market share increased to 579% of total prescriptions, with market growth of 36% versus prior year[10, 26] - Mounjaro U S sales were $36 billion, and international sales were $30 billion[56] - Zepbound U S sales were $36 billion, and international sales were $20 million[59] - Verzenio U S sales were $880 million, and international sales were $590 million[62] - Jaypirca Q3 2025 sales were $143 million, with U S TRx increasing 61% vs Q3 2024[24] - Ebglyss Q3 2025 sales were $127 million, with U S TRx growing 41% vs Q2 2025[24] - Omvoh Q3 2025 sales were $65 million[24] - Kisunla Q3 2025 sales were $70 million[24] Strategic Investments - Year-to-date capital investments totaled $53 billion[12] - Research & Development investment was $35 billion, representing 27% of revenue[12] - Marketing, selling & administrative expenses were $27 billion, a 31% increase[12] - $13 billion was distributed via dividends and $07 billion in share repurchases[14] Regulatory and Clinical Updates - Inluriyo (imlunestrant) received U S FDA approval for ER+, HER2-, ESR1-mutated advanced or metastatic breast cancer[11] - Kisunla received marketing authorization in Europe for early symptomatic Alzheimer's disease[11] - Orforglipron showed positive results in four additional Phase 3 trials[11] - Jaypirca significantly improved progression-free survival in treatment-naïve CLL/SLL[11]

Financial Performance & Growth - Saia's estimated total market share in 2024 was 6.8%, up from 4.0% in 2017[21] - Saia's 7-year annual revenue CAGR of 13% vs the Top 10 LTL Peers average of 9% and LTL industry average of 5.9%[17] - Q3 2025 revenue was $839.6 million, a decrease of 0.3% compared to $842.1 million in Q3 2024[41] - Adjusted operating income for Q3 2025 was $104.1 million, a decrease of 16.8% compared to $125.2 million in Q3 2024[41] - Adjusted diluted earnings per share for Q3 2025 was $2.81, a decrease of 18.8% compared to $3.46 in Q3 2024[41] Investments & Expansion - Over $2 billion has been invested in the business since 2021, largely driven by operating cash flow[12] - Approximately $550 million to $600 million is planned for investment in 2025 to better support customer needs[12] - 69 terminals have been opened since the start of 2017, including in the Great Plains region, expanding Saia's footprint to a national network[12] - Approximately 61% of zip codes are within 50 miles of a Saia facility, up from approximately 35% in 2017[34] Operational Metrics - Revenue per shipment in Q3 2025 was $349.07[40] - Pounds per shipment in Q3 2025 was 1,355[40] - Length of haul in Q3 2025 was 894 miles[40]